Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Speeds up approval of medicines for children's diseases.
The problem
Developing drugs for pediatric diseases takes time and money. Companies may not prioritize treatments for children because smaller markets mean less profit.
The proposal
Creates faster regulatory pathways and gives incentives for pharmaceutical companies to develop cures and treatments specifically for pediatric conditions.
The impact
Drug companies, children with rare diseases, and FDA gain options. Sick children might get treatments faster. Companies may invest more in pediatric medicines.
Speedier approval means children with serious diseases could get new medicines sooner. This could save lives and reduce suffering. Families would have more treatment options available.
Financial rewards encourage pharmaceutical companies to develop medicines for children. Companies spend billions on drug development, so incentives help balance costs. This creates more pediatric treatment options overall.
Few companies develop drugs just for children because the market is small. This bill removes barriers and rewards companies for filling this gap. More pediatric medicines become available as a result.
Faster approval processes might skip important safety testing. Children are vulnerable, and rushing drug reviews could miss serious side effects. Balancing speed with safety is challenging.
Tax incentives and faster approvals may increase drug prices for families. Companies might charge more knowing they got expedited treatment. Insurance costs could rise for everyone.
Incentives work best for common pediatric diseases with large markets. Very rare childhood diseases may still get ignored because profits are too small. Low-income families might benefit less than wealthy ones.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.